Study reveals how question order skews depression scores in scleroderma patients
NCT ID NCT06772896
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at whether the way depression questions are asked changes how people with scleroderma report physical symptoms like sleep problems, fatigue, and appetite changes. Over 800 participants were randomly assigned to answer the same depression questionnaire either in the standard order or with the physical symptom questions placed first and separately. The goal was to see if knowing they were being assessed for depression influenced their answers about physical symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help researchers design better depression questionnaires for people with chronic illnesses, leading to more accurate mental health assessments.
- What could go wrong
- This is a completed observational study, not a treatment trial. The results may not change clinical practice or directly benefit participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Lady Davis Institute for Medical Research
Montreal, Quebec, H3T 1E2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new pill ease the hardening skin of systemic sclerosis?
- A drug after transplant may stop scleroderma from coming back
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.